1. Introduction {#sec1-cancers-11-00609}
===============

In 2014, more than 18,500 people in Germany were initially diagnosed with rectal cancer (11,414 males and 7281 females) \[[@B1-cancers-11-00609]\], along with 7605 rectal cancer deaths (4519 in males and 3086 in females) \[[@B1-cancers-11-00609]\]. The 5-year survival rate for rectal cancer increased in the 21st century from 44.3% in the early nineties (1990 to 1992) to 53.7% in the period of 2000--2002, earlier detection and progress in therapy being the cause \[[@B2-cancers-11-00609]\]. Colorectal cancer is responsible for the third highest economic cost (13.1 Billion €, 10% of all cancer costs) in the European Union behind lung (18.8 billion €, 15%) and breast cancer (15.0 billion €, 12%). Regarding health care costs colorectal cancer (5.57 billion €, 11% of all-cancer related health care costs) was ranked second behind breast cancer (6.73 billion €, 13%) followed by prostate cancer (5.43 billion €, 11%) \[[@B3-cancers-11-00609]\].

Obesity is a well-known risk-factor for the development of colorectal cancer \[[@B4-cancers-11-00609],[@B5-cancers-11-00609]\]. Adiposity triggers several systemic and metabolic alterations that can influence carcinogenesis. It has been shown that obesity is related to enhanced levels of leptin in humans, leading to increasing total numbers of cells in different colonic tissues \[[@B6-cancers-11-00609]\]. In addition, leptin was associated with reducing apoptosis in various in vitro experiments \[[@B6-cancers-11-00609]\]. These observations suggest that, in some cases, an un-physiological elevation of leptin might become a risk factor for tumor growth.

In a prospective cohort study, performed in the period from 1986 until 1992, the Body Mass Index (BMI) of 47,723 male patients was correlated with the incidence of colorectal cancer or adenoma. Thereby, BMI was identified as a direct risk factor for the development of colorectal cancer independent of physical activity \[[@B7-cancers-11-00609]\]. A meta-analysis of 31 studies performed in 2007 identified a dose-response correlation between BMI and colorectal cancer, showing that an increase of 2 kg/m^2^ elevated the risk for colorectal cancer by 7% \[[@B8-cancers-11-00609]\]. Underweight impaired the early and long-term survival after rectal cancer surgery in a multicenter observational study \[[@B9-cancers-11-00609]\].

However, the effect of the BMI on the long-term survival for patients with rectal carcinoma has not been assessed in detail. The aim of our study was therefore to investigate the influence of BMI on the long-term survival of patients diagnosed with rectal cancer.

2. Results {#sec2-cancers-11-00609}
==========

2.1. Subject Characteristics {#sec2dot1-cancers-11-00609}
----------------------------

The median follow-up time for 612 patients was 93 (range 2--156) months. The male-to-female ratio was 1.97 to 1. The mean age was 65 years (range 18--91), there was no significant difference for age \<65 and ≥65 between the BMI-groups as classified by the World Health Organisation (WHO) or Group 1 and 2. Female patients were more likely to be underweight than male patients, whereas male patients showed higher rates of overweight, obesity class I and obesity class II. Underweight and obese patients had a higher perioperative risk as classified by the American Society of Anaesthesiologists (ASA) scoring (1--4) (*p* = 0.005). An ASA-Score of 3 or 4 was found more often in individuals graded as underweight, obese class I, obese class II and obese class III. Group 2 showed a significantly higher rate of ASA-Score 3 or 4, compared to Group 1 (*p* = 0.004). CEA-levels were significantly more often elevated in Group 2 compared to patients in Group 1 (*p* = 0.048). Furthermore, patients in Group 2 were more likely to receive a multivisceral resection than patients in Group 1 (*p* = 0.042). Except for this, no significant differences for the tumour or patient characteristics could be demonstrated for Group 1 and 2. Further characteristics of the patients, tumours and the treatment details are shown in [Table 1](#cancers-11-00609-t001){ref-type="table"} and [Table 2](#cancers-11-00609-t002){ref-type="table"}.

2.2. Quality Indicators {#sec2dot2-cancers-11-00609}
-----------------------

The median number of examined lymph nodes was 21 (range 2--76). Microscopic curative tumor resection rates were significantly lower in patients who were underweight (*p* = 0.031), without significant differences between patients in Group 1 and 2 (*p* = 0.238). Other than that, there was no discernible difference concerning the surgical quality indicators, showing no significance for aboral (*p* = 0.474) and circumferential (*p* = 0.445) resection margin or intraoperative local tumor cell dissemination (*p* = 0.186). The specimen quality was considered to be good in 555 patients (97.2%) without a significant dependency on BMI (WHO, *p* = 0.309; Group1 and 2, *p* = 0.203). The number of abdominoperineal excision (APE) was performed more often in underweight, obese class II and obese class III patients compared to normal weight, overweight, and obese class I patients, but did not reach significance (*p* = 0.074). Group 1 showed a lower rate of APR compared to Group 2 (15.3 vs. 31%, *p* = 0.025). A primary anastomosis was conducted in 82.5% with lower count in underweight, obese class II and obese class III individuals (*p* = 0.019) without reaching significant differences for anastomotic leakage (*p* = 0.466, 4.3% overall). General postoperative morbidity was increased in underweight, obese class II and obese class III patients compared to normal weight, overweight and obese class I individuals (*p* = 0.008). Surgical complications were significantly increased in the same patient collective (*p* = 0.006), whereas non-surgical complications showed no differences for BMI (*p* = 0.460). The postoperative 30-day mortality was 1.0% and did not depend on BMI (*p* = 0.116). Further data on quality indicators is shown in [Table 3](#cancers-11-00609-t003){ref-type="table"}.

2.3. Local Recurrence {#sec2dot3-cancers-11-00609}
---------------------

The 5-year rate for local recurrence in the entire study group was 5.9% (95% CI 3.9--7.9). Neither localisation of the tumour nor type of surgery or CEA-level had a significant influence on the 5-year local recurrence. Obesity class II and the presence of perioperative risk factors (ASA 3 and 4) showed a significant increment for local recurrence ([Table 4](#cancers-11-00609-t004){ref-type="table"}).

2.4. Distant Metastasis {#sec2dot4-cancers-11-00609}
-----------------------

Distant metastases occurred in 16.7% (95% CI 13.6--19.8) of all patients in a 5-year observational period. Patients in Group 2 showed a rate of metastatic disease in 31.4% (95% CI 14.3--48.5) of cases while patients in Group 1 showed a significantly lower rate of 15.9% (95 CI 12.8--19.0; *p* = 0.034) ([Figure 1](#cancers-11-00609-f001){ref-type="fig"}). Significant differences between the BMI Groups as defined by the WHO did not occur.

Type of surgery, the preoperative ASA-Score and localisation of the tumour had no significant influence. Individuals with preoperative CEA levels over 5 ng/L had a significantly higher rate of distant metastases and an increased risk to develop distant metastases ([Table 5](#cancers-11-00609-t005){ref-type="table"}).

2.5. Overall Survival {#sec2dot5-cancers-11-00609}
---------------------

The 5-year overall survival was analyzed for 598 patients with an overall survival rate of 82.3% (CI 79.2--85.4). Patients in Group 1 (BMI 18.5--35 kg/m^2^) showed an overall survival of 82.9% (95% CI 79.8--86.0), which was significantly higher than in Group 2 (\<18.5 or ≥35 kg/m^2^) with 70.0% (95% CI 53.5--86.5; *p* = 0.024) ([Figure 2](#cancers-11-00609-f002){ref-type="fig"}). No difference was observed between the BMI Groups as suggested by the WHO.

The localisation of the tumour had no significant impact, however APE was associated with a significantly lower survival rate. The presence of systemic disabilities, as classified by the ASA-Score, influenced the overall survival. Patients with an ASA-Score of 3 or 4 had a significantly lower 5-year-survial in this period of time. Elevated preoperative CEA-levels were also related to a lower 5-year survival and an increased mortality risk ([Table 6](#cancers-11-00609-t006){ref-type="table"}).

3. Discussion {#sec3-cancers-11-00609}
=============

In the past years BMI has been proven to be a significant risk factor, or at least a surrogate parameter, for the development of colorectal cancer by different studies \[[@B8-cancers-11-00609],[@B10-cancers-11-00609],[@B11-cancers-11-00609],[@B12-cancers-11-00609]\]. However, the evidence for BMI being a predictor of outcome in patients with rectal cancer undergoing surgical therapy is still discussed controversially.

Various trials have shown that underweight or obesity are risk factors for reduced survival in colorectal cancer diseases \[[@B13-cancers-11-00609],[@B14-cancers-11-00609],[@B15-cancers-11-00609],[@B16-cancers-11-00609],[@B17-cancers-11-00609],[@B18-cancers-11-00609]\]. Therefor we decided to search for an indicator in these patients by dividing our patient cohort into two groups (Group 1 BMI 18.5--35 kg/m^2^; Group 2 BMI \<18.5 and ≥35 kg/m^2^).

3.1. Quality Indicators {#sec3dot1-cancers-11-00609}
-----------------------

We detected differences in the rate of abdominoperineal excision (APE) between tumors in the low and middle third (45.6% vs. 3.9%, *p*-value \< 0.001) of the rectum, but we were not able to confirm the disparate use of APE by sex, with a decreased rate among female patients with rectal cancer, as reported by a previous survey \[[@B17-cancers-11-00609]\]. Patients included in our study, treated by APE, had a reduced survival compared to those treated by other surgical procedures (APE vs. other procedures: 73.0% vs. 83.9%; HR 2.0, *p*-value \< 0.001), however, we did not see differences for distant metastases (18.0% vs. 16.4%, *p*-value 0.313) or local recurrence (8.9% vs. 5.4%, *p*-value 0.104). These findings are concordant to a study on 1598 patients with low and mid rectal cancer treated in 38 hospitals being part of the Spanish Rectal Cancer Project \[[@B18-cancers-11-00609]\]. One possible hypothesis is that different patient characteristics, rather than the surgical procedure (APE) itself, cause a difference in oncological outcome in patients undergoing APE \[[@B19-cancers-11-00609]\].

Postoperative complications were seen in 22.2% of all patients with a significantly higher percentage in underweight and obese class II and III patients. Previous studies have shown that morbidity influences the overall survival (OS) in patients with various tumor diseases \[[@B20-cancers-11-00609],[@B21-cancers-11-00609],[@B22-cancers-11-00609]\]. We were able to confirm these results in our study (OS Morbidity vs. no Morbidity: 76.5% vs. 83.9%, *p*-value 0.004). No differences in non-surgical complications could be observed, indicating the differences in morbidity are caused by perioperative complications like wound dehiscence, anastomotic insufficiency or ileus, as reported in other studies \[[@B23-cancers-11-00609],[@B24-cancers-11-00609],[@B25-cancers-11-00609]\]. One major factor leading to reduced overall survival in patients with postoperative complications is the reduced ability to receive adjuvant treatment \[[@B26-cancers-11-00609],[@B27-cancers-11-00609],[@B28-cancers-11-00609]\]. Interestingly, we did not see any differences in adjuvant treatment rates between the BMI-groups, which leaves the mechanism behind the observed differences in the overall survival unanswered.

3.2. Local Recurrence (LR) {#sec3dot2-cancers-11-00609}
--------------------------

Tumor localization in the rectum is known to affect the risk for the development of LR after primary curative surgical resection in rectal cancer patients \[[@B29-cancers-11-00609]\]. Reduced surgical visibility in obese patients with lower rectal tumors compromising sufficient resection, are possible responsible factors. Despite these findings, patients included in our study did not show significantly higher rates of LR dependent on tumor localization, which might be correlated to the surgical procedure. APE has been proven to be a significant risk factor for LR in patients with rectal carcinoma \[[@B30-cancers-11-00609]\]. Our patient cohort did not show the same dependency. Localization in the lower rectum or advanced tumor stage are common reasons to perform APE. While anatomy and tumor localization may be reasons for increased recurrences, tumor biology is another explanation worth considering. Obesity is associated with insulin resistance and consequently higher rates of circulating insulin \[[@B31-cancers-11-00609]\] leading to a higher bioactivity of Insulin-like-growth factor 1 (IGF-1). IGF-1 promotes a series of intracellular signaling cascades leading to mitogenic and antiapoptotic events, a risk factor for recurrence and tumor growth \[[@B32-cancers-11-00609],[@B33-cancers-11-00609]\]. No relation was seen between LR and tumor localization, whereas an advanced tumor stage increased LR risk.

3.3. Distant Metastasis (DM) {#sec3dot3-cancers-11-00609}
----------------------------

We were able to show a correlation of DM-rates by BMI and the UICC-stage. Our study population displayed increased rates of DM in patients with high or very low BMI (\<18.5 or ≥35 kg/m^2^). The disparate appearance of DM might be due to molecular mechanisms as suggested by different studies pointing on inflammatory cytokines such as insulin-like growth factor-receptor (IGF-R) and leptin \[[@B34-cancers-11-00609],[@B35-cancers-11-00609],[@B36-cancers-11-00609],[@B37-cancers-11-00609]\]. With obesity inducing a state of slight inflammation and changing the microenvironment for example in steatotic livers, this might be a reason for higher rates of DM in very obese patients \[[@B38-cancers-11-00609]\]. Unfortunately, we have not been able to confirm this hypothesis due to missing blood samples for the patients included within this analysis. In underweight patients instead, the earlier infiltration of blood and lymph vessels can be seen as a factor for higher DM-rates.

The possibility to provide adjuvant tumor therapy for patients with DM was diverging due to BMI (Group 1 vs. Group 2: 69.8% vs. 60.0%, *p*-value 0.036). This may be an effect of comorbidities in patients with high and very low BMI.

3.4. Overall Survival {#sec3dot4-cancers-11-00609}
---------------------

Patients with advanced tumors are known to have a decreased time of overall survival \[[@B39-cancers-11-00609]\]. This circumstance is reflective of the advanced stage of the tumor-disease.

The results of our study suggest an association between BMI and overall survival and are consistent with a study performed on 526 patients, determining a link between BMI and patients outcome diagnosed with left-sided cancer and rectal cancer \[[@B40-cancers-11-00609]\]. Reduced survival in patients with obesity class II or higher as well as underweight (Group 2) compared to normal weight, overweight and obesity class I (Group 1) individuals, may be related to higher rates of distant metastases (DM) found in this group. At least the lower survival rate in patients with underweight might be derived from an advanced tumor stage causing a catabolic metabolism. Weight-loss promoted by this catabolic situation could be a factor shifting patients with normal weight to underweight at the time of hospital admission \[[@B9-cancers-11-00609]\]. Chemotherapy-related toxicities and other complications had been observed in slightly lower numbers in obese patients compared to non-obese patients in some adjuvant therapy trials \[[@B14-cancers-11-00609],[@B41-cancers-11-00609]\]. The possibility to provide appropriate postoperative tumor therapy can be suggested as a factor for better survival in obese patients.

Tumor localization in contrast to other trials, had no significant impact on the overall survival of patients included in this study \[[@B42-cancers-11-00609]\]. This may be reflective of a good surgical quality independent of difficult conditions.

The strength of our study is the large sample size, stage specific data and the long-term follow-up data with at least 5-years follow up-time for each patient, as well as completeness of the data. On the other hand, this study has certain limitations: we performed a retrospective analysis of prospectively collected data. The small number of patients in the subgroups as well as the design as a single center study reduced the validity of our conclusions.

4. Materials and Methods {#sec4-cancers-11-00609}
========================

The initially screened study cohort consisted of patients diagnosed with rectal cancer at the University Hospital Erlangen in the time of January 2003 until December 2010. All of these patients underwent surgery for the treatment of rectal carcinoma in the department of surgery at the University Hospital Erlangen. Patient data were selected on the following inclusion criteria: Solitary invasive rectal carcinoma (at least infiltration of the submucosa) ≤16 cm from anal verge when measured with a rigid sigmoidorectoscope; treated by (low) anterior resection, Hartmann procedure, intersphincteric resection or abdominoperineal excision; no other malignant tumors either synchronous with or prior to diagnosis; no history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease; no distant metastasis (M0) at the time of diagnosis. 6 patients without valid BMI, 6 patients who died postoperatively and three patients with unknown tumor-status were excluded from the analysis.

Only patients with microscopic curative resection (R0) were used for outcome analyses. Consequently, a total of 598 patients were included for these analyses.

To calculate surgical quality indicators like R0-resection rate in [Table 3](#cancers-11-00609-t003){ref-type="table"} we included all patients independent of their resection status (R0 (*n* = 598) + R1 (*n* = 9) + R2 (*n* = 5) = 612).

Long-term chemoradiation was administered in the majority of patients after preoperative staging (cT3, 4 or cN+ \[[@B43-cancers-11-00609]\]), in concordance to the protocol of the German CAO/ARO/AIO-94 study \[[@B44-cancers-11-00609]\]. The neoadjuvant treatment was finished 6--8 weeks prior to surgery.

All samples were categorized according to the seventh edition of the UICC TNM classification \[[@B45-cancers-11-00609]\].

According to the definition of the World Health Organization (WHO) the patient cohort was divided in six groups, i.e., underweight (BMI \< 18.5 kg/m^2^; *n* = 5); normal weight (BMI 18.5--24,9 kg/m^2^; *n* = 209); overweight (BMI 25.0--29.9 kg/m^2^; *n* = 257); obesity class I (BMI 30.0--34.9 kg/m^2^; *n* = 102); obesity class II (BMI 35.0--39.9 kg/m^2^; *n* = 16); and obesity class III (BMI ≥ 40.0 kg/m^2^; *n* = 9) \[[@B46-cancers-11-00609]\]. BMI was measured in the anaesthesia outpatient clinic during preparation for surgery at the time of first hospital admission at the University Hospital Erlangen.

To meet the challenge of a society with an increasing prevalence of obesity in the last 30 years \[[@B47-cancers-11-00609]\], we divided the study population in two groups (Group 1 BMI 18.5-- 35 kg/m^2^; *n* = 568; Group 2 BMI \<18.5 and ≥35 kg/m^2^; *n* = 30) with Group 1 representing the dominant phenotype in future communities.

Patients with tumors in the lower and middle rectum received a total mesorectal excision (TME). Partial mesorectal excision (PME) or TME was performed if suitable in patients with tumour in the upper part of the rectum. The quality of TME or PME was examined in accordance to the protocol of Quirke et al. by a pathologist \[[@B48-cancers-11-00609]\].

All patients were followed up with for at least 5 years: twice a year, for the first 2 years and then yearly for the remaining period as suggested by the first edition of the German S3-Guidelines for Colorectal Carcinoma \[[@B43-cancers-11-00609]\]. Follow-ups included physical examination, analysis of carcinoembryonic antigen (CEA) levels, chest X-ray, abdominal ultrasonography, computed tomography of the pelvis and rectoscopy.

Follow-up data were either collected by standard follow-up examinations at the University hospital Erlangen or by written correspondence with the patient's general practitioner. Subsequently the vital status of the patient was validated through inquiries at the patient's local registration office and all data have been collected and categorized by our local cancer registry.

All subjects gave their informed consent for inclusion before they participated in this study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany (172_19 Bc).

Statistical Analysis
--------------------

To compare categorical data $\mathsf{\chi}$^2^ and Fisher's exact test were used. For quantitative data the Mann-Whitney *U* test was applied. The Kaplan-Meier method was utilized to analyze the five-year rates of local recurrence, distant metastasis and overall survival; the log-rank test was applied for comparison of the survival curves. For overall survival death from any cause was defined as an event. To analyze univariable and multivariable differences in local recurrence, distant metastasis or overall survival, a Cox-regression model was used. A *p*-value \< 0,050 was considered to be significant.

The statistical software package SPSS^®^ version 24 (IBM, Armonk, NY, USA) was used for all analyses.

5. Conclusions {#sec5-cancers-11-00609}
==============

We were able to show differences in survival rates depending on BMI values. The increased rate of distant metastases as well as the higher rates of APE in Group 2 might be due to patient selection in our cohort. Patients treated by APE had a 2-fold risk of death, but no elevated rates of DM. LR increased the rate of DM by a factor of 3,6, but showed no impact on overall survival.

The present work was performed in fulfilment of the requirements for obtaining the degree "med." at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
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cancers-11-00609-t001_Table 1

###### 

Demographics, tumour and treatment characteristics of 612 patients.

  Patient Characteristics           Number        Percent
  --------------------------------- ------------- ---------
  Age (years), median (range)       65 (18--91)   
  Sex                                             
      Male                          406           66.3
      Female                        206           33.7
  BMI Groups                                      
      Group 1 BMI 18.5--35          580           94.8
      Group 2: BMI \<18.5 & ≥35     32            5.2
  BMI WHO                                         
      \<18.5 underweight            7             1.1
      18.5--24.9 normal weight      212           34.6
      25.0--29.9 overweight         266           43.5
      30.0--34.9 class I obesity    102           16.7
      35.0--39.9 class II obesity   16            2.6
      ≥40.0 class III obesity       9             1.5
  Tumour site                                     
      \<6 cm lower third            211           34.5
      6--12 cm middle third         276           45.1
      12--16 cm upper third         125           20.4
  ASA-Score                                       
      ASA 1 & 2                     490           80.1
      ASA 3 & 4                     118           19.3
      Missing                       4             0.7
  Pretherapy CEA level                            
      normal(\<5 ng/L)              438           71.6
      raised(\>10 ng/L)             94            15.4
      Missing                       80            13.1
  Neoadjuvant therapy                             
      neoadjuvant RCT               320           52.3
      neoadjuvant RT                4             0.7
      neoadjuvant CT                1             0.2
      None                          287           46.9
  Elective surgery                                
      Yes                           606           99.0
      No, Emergency                 6             1.0
  Type of surgery                                 
      Anterior resection            77            12.6
      Low anterior resection        378           61.8
      Hartmann procedure            8             1.3
      Intersphincteric resection    50            8.2
      Abdominoperineal excision     99            16.2
  Multivisceral resection                         
      No                            520           85.0
      Yes                           92            15.0
  Postoperative therapy                           
      None                          70            11.4
      CT                            171           27.9
      RT                            4             0.7
      RCT                           56            9.2
      unknown                       311           50.8
  pT-category                                     
      pT1                           66            10.8
      pT2                           103           16.8
      pT3                           100           16.3
      pT4                           18            2.9
      ypT0                          60            9.8
      ypT1                          13            2.1
      ypT2                          113           18.5
      ypT3                          120           19.6
      ypT4                          19            3.1
  pN-category                                     
      pN0                           217           35.5
      pN1                           46            7.5
      pN2                           24            3.9
      ypN0                          235           38.4
      ypN1                          69            11.3
      ypN2                          21            3.4
  UICC-stage                                      
      I                             150           24.5
      II                            67            10.9
      III                           70            11.4
      y0                            55            9.0
      yI                            101           16.5
      yII                           79            12.9
      yIII                          90            14.7

ypT: pathological tumour category after chemoradiation, ypN: pathological node category after chemoradiation, BMI: Body Mass Index, WHO: World Health Orga, ASA: American Society of Anaesthesiologists, CEA: Carcinoembryonic antigen, RCT: Radiochemotherapy, CT: Chemotherapy, UICC: Union internatonale contre le cancer.

cancers-11-00609-t002_Table 2

###### 

Demographics, tumour and treatment characteristics of 612 patients for BMI-groups.

  Patient Characteristics       \<18.5 kg/m^2^ Underweight (*n* = 7)   18.5--25 kg/m^2^ Normal Range (*n* = 212)   25--30 kg/m^2^ Overweight (*n* = 266)   30--35 kg/m^2^ Obese Class I (*n* = 102)   35--40 kg/m^2^ Obese Class II (*n* = 16)   ≥40 kg/m2 Obese Class III (*n* = 9)   *p*     Group 1: BMI 18.5--35 (*n* = 580)   Group 2: BMI \<18.5 & ≥35 (*n* = 32)   *p*
  ----------------------------- -------------------------------------- ------------------------------------------- --------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------- ------- ----------------------------------- -------------------------------------- -------
  Age                                                                                                                                                                                                                                                                                                                                                                     
   \< 65                        6 (86)                                 118 (55.7)                                  137 (51.5)                              45 (44.1)                                  8 (50)                                     6 (67)                                        300 (51.7)                          20 (63)                                
   ≥ 65                         1 (14)                                 94 (44.3)                                   129 (48.5)                              57 (55.9)                                  8 (50)                                     3 (33)                                0.180   280 (48.3)                          12 (37)                                0.277
  Sex                                                                                                                                                                                                                                                                                                                                                                     
   Male                         3 (43)                                 122 (57.5)                                  196 (73.7)                              69 (67.6)                                  11 (69)                                    5 (56)                                        387 (66.7)                          19 (59)                                
   Female                       4 (57)                                 90 (42.5)                                   70 (26.3)                               33 (32.4)                                  5 (31)                                     4 (44)                                0.005   193 (33.3)                          13 (41)                                0.443
  Tumour site                                                                                                                                                                                                                                                                                                                                                             
   \<6cm lower third            4 (57)                                 83 (39.2)                                   82 (30.8)                               34 (33.3)                                  5 (31)                                     3 (33)                                        199 (34.3)                          12 (38)                                
   \<12 cm middle third         3 (43)                                 84 (39.6)                                   132 (49.6)                              43 (42.2)                                  9 (56)                                     5 (56)                                        259 (44.7)                          17 (53)                                
   ≤16cm upper third            0 (0)                                  45 (21.2)                                   52 (19.6)                               25 (24.5)                                  2 (13)                                     1 (11)                                0.416   122 (21.0)                          3 (9)                                  0.269
  ASA-Score ^a^                                                                                                                                                                                                                                                                                                                                                           
   ASA 1&2                      4 (57)                                 181/211 (85.8)                              215/264 (81.4)                          75/101 (74.3)                              9 (56)                                     6 (67)                                        471/576 (81.8)                      19 (59)                                
   ASA 3&4                      3 (43)                                 30/211 (14.2)                               49/264 (18.6)                           26/101 (25.7)                              7 (44)                                     3 (33)                                0.005   105/576 (18.2)                      13 (41)                                0.004
  Pretherapy CEA level ^b^                                                                                                                                                                                                                                                                                                                                                
   Normal (\<5 ng/L)            3/6 (50)                               143/176 (81.3)                              196/231 (84.8)                          78/94 (83.0)                               9 (56)                                     9 (100)                                       417/501 (83.2)                      21/31 (68)                             
   Elevated (≥5 ng/L)           3/6 (50)                               33/176 (18.7)                               35/231 (14.2)                           16/94 (17.0)                               7 (44)                                     0 (0)                                 0.018   84/501 (16.8)                       10/31 (32)                             0.048
  Neoadjuvant therapy                                                                                                                                                                                                                                                                                                                                                     
   Neoadjuvant RCT              6 (86)                                 117 (55.2)                                  133 (50.0)                              52 (51.0)                                  9 (56)                                     9 (47)                                        302 (52.1)                          18 (56)                                
   Neoadjuvant RT               0 (0)                                  1 (0.5)                                     3 (1.1)                                 0 (0.0)                                    0 (0)                                      0 (0)                                         4 (0.7)                             0 (0)                                  
   Neoadjuvant CT               0 (0)                                  0 (0.0)                                     1 (0.4)                                 0 (0.0)                                    0 (0)                                      0 (0)                                         1 (0.1)                             0 (0)                                  
   None                         1 (14)                                 94 (44.3)                                   129 (48.5)                              50 (49.0)                                  7 (44)                                     10 (53)                               0.635   273 (47.1)                          14 (44)                                0.786
  Elective surgery                                                                                                                                                                                                                                                                                                                                                        
   Yes                          7 (100)                                208 (98.1)                                  264 (99.2)                              102 (100)                                  16 (100)                                   9 (100)                                       574 (99.0)                          32 (100)                               
   No, Emergency                0 (0)                                  4 (1.9)                                     2 (0.8)                                 0 (0.0)                                    0 (0)                                      0 (0)                                 0.523   6 (1.0)                             0 (0)                                  1.0
  Type of surgery                                                                                                                                                                                                                                                                                                                                                         
   Anterior resection           0 (0)                                  32 (15.1)                                   28 (10.5)                               15 (14.7)                                  1 (6)                                      1 (11)                                        75 (12.9)                           2 (6)                                  
   Low anterior resection       2 (29)                                 126 (59.4)                                  177 (66.5)                              59 (57.8)                                  9 (56)                                     5 (56)                                        362 (62.4)                          16 (50)                                
   Hartmann procedure           1 (14)                                 3 (1.4)                                     3 (1.1)                                 1 (1.1)                                    0 (0)                                      0 (0)                                         7 (1.3)                             1 (3)                                  
   Intersphincteric resection   0 (0)                                  15 (7.1)                                    19 (7.1)                                13 (12.7)                                  2 (13)                                     1 (11)                                        47 (8.1)                            3 (9)                                  
   Abdominoperineal excision    4 (57)                                 36 (17.0)                                   39 (14.8)                               14 (13.7)                                  4 (25)                                     2 (22)                                0.863   89 (15.3)                           10 (32)                                0.086
  Multivisceral resection                                                                                                                                                                                                                                                                                                                                                 
   No                           3 (43)                                 181 (85.4)                                  228 (85.7)                              88 (86.3)                                  13 (81)                                    7 (78)                                        497 (85.7)                          23 (72)                                
   Yes                          4 (57)                                 31 (14.6)                                   38 (14.3)                               14 (13.7)                                  3 (19)                                     2 (22)                                0.098   83 (14.3)                           9 (28)                                 0.042
  Postoperative therapy ^c^                                                                                                                                                                                                                                                                                                                                               
   RCT                          0/6 (0)                                19/105 (18.1)                               26/127 (20.5)                           8/49 (16.3)                                1/9 (11)                                   2/5 (40)                                      53/281 (18.9)                       3/20 (15)                              
   Radiotherapy                 0/6 (0)                                0/ 105 (0.0)                                2/127 (1.6)                             2/49 (4.2)                                 0/9 (0)                                    0/5 (0)                                       4/281 (1.4)                         0/20 (0)                               
   Chemotherapy                 5/6 (83.3)                             55/105 (52.4)                               77/127 (60.6)                           28/49 (57.1)                               5/9 (56)                                   1/5 (20)                                      160/281 (56.9)                      11/20 (55)                             
   None                         1/6 (16.7)                             31/105 (29.5)                               22/127 (17.3)                           11/49. (22.4)                              3/9 (33)                                   2/5 (40)                              0.320   64/281 (22.8)                       6/20 (30)                              0.856
  pT-category                                                                                                                                                                                                                                                                                                                                                             
   pT1                          0 (0)                                  22 (10.4)                                   25 (9.4)                                14 (13.7)                                  2 (13)                                     3 (34)                                        61 (10.5)                           5 (16)                                 
   pT2                          0 (0)                                  31 (14.6)                                   49 (18.4)                               20 (19.6)                                  2 (13)                                     1 (11)                                        100 (17.2)                          3 (9)                                  
   pT3                          1 (14)                                 34 (16.0)                                   45 (16.9)                               15 (14.7)                                  3 (19)                                     2 (22)                                        94 (16.2)                           6 (19)                                 
   pT4                          0 (0)                                  7 (3.3)                                     10 (3.8)                                1 (1.1)                                    0 (0)                                      0 (0)                                         18 (3.2)                            0 (0)                                  
   ypT0                         0 (0)                                  22 (10.4)                                   29 (10.9)                               7 (6.9)                                    1 (6)                                      1 (11)                                        58 (10.0)                           2 (6)                                  
   ypT1                         0 (0)                                  5 (2.4)                                     7 (2.6)                                 1 (1.1)                                    0 (0)                                      0 (0)                                         13 (2.2)                            0 (0)                                  
   ypT2                         1 (14)                                 46 (21.7)                                   45 (16.9)                               18 (17.5)                                  3 (19)                                     0 (0)                                         109 (18.8)                          4 (13)                                 
   ypT3                         3 (43)                                 39 (18.4)                                   48 (18.0)                               24 (23.5)                                  4 (24)                                     2 (22)                                        111 (19.1)                          9 (28)                                 
   ypT4                         2 (29)                                 6 (2.8)                                     8 (3.1)                                 2 (1.9)                                    1 (6)                                      0 (0)                                 0.110   16 (2.8)                            3 (9)                                  0.333
  pN-category                                                                                                                                                                                                                                                                                                                                                             
   pN0                          1 (14)                                 67 (31.6)                                   100 (37.6)                              42 (41.2)                                  4 (25)                                     3 (33)                                        209 (36.0)                          8 (25)                                 
   pN1                          0 (0)                                  16 (7.5)                                    20 (7.5)                                6 (5.9)                                    2 (13)                                     2 (23)                                        42 (7.2)                            4 (13)                                 
   pN2                          0 (0)                                  11 (5.2)                                    9 (3.4)                                 2 (2.0)                                    1 (6)                                      1 (11)                                        22 (3.8)                            2 (6)                                  
   ypN0                         3 (43)                                 90 (42.5)                                   102 (38.3)                              30 (29.4)                                  7 (44)                                     3 (33)                                        222 (38.3)                          13 (41)                                
   ypN1                         2 (29)                                 21 (9.9)                                    26 (9.8)                                19 (18.6)                                  1 (6)                                      0 (0)                                         66 (11.4)                           3 (9)                                  
   ypN2                         1 (14)                                 7 (3.3)                                     9 (3.4)                                 3 (2.9)                                    1 (6)                                      0 (0)                                 0.140   19 (3.3)                            2 (6)                                  0.408

^a^ 4 Patients excluded due to unknown ASA-Score, ^b^ 80 Patients excluded due to unknown CEA-level, ^c^ 311 patients excluded due to missing data on postoperative therapy, Values in parentheses are percentages.

cancers-11-00609-t003_Table 3

###### 

Surgical quality indicators for 612 patients.

  Quality Indicators                                                \<18.5 Underweight *n* = 7)   18.5--25 Normal Weight (*n* = 212)   25--30 Overweight (*n* = 266)   30--35 Obese Class I (*n* = 102)   35--40 Obese Class II (*n* = 16)   ≥40 Obese Class III (*n* = 9)   *p*       Group 1: 18.5--35 (*n* = 580)   Group 2: \<18.5 & ≥ 35 (*n* = 32)   *p*
  ----------------------------------------------------------------- ----------------------------- ------------------------------------ ------------------------------- ---------------------------------- ---------------------------------- ------------------------------- --------- ------------------------------- ----------------------------------- ---------
  Number of examined LN; R0, R1, R2 *n* = 612 ^a^, median (range)   13 (11--33)                   20 (2--57)                           21.5 (3--62)                    21 (5--76)                         23.5 (8--57)                       30 (15--43)                               21 (2--76)                      25.5 (8 -- 57)                      
  ≥ 12 LN examined                                                  6/7 (86)                      188/212 (88.7)                       239/266 (89.8)                  93/102 (91.2)                      15/16 (94)                         9/9 (100)                       0.828     520/580 (89.7)                  30/32 (94)                          0.742
  pN0 *n* = 217, median (range)                                     33 (33--33)                   24 (12--51)                          27 (7--57)                      31 (10--76)                        30 (22--36)                        26 (15--41)                               26 (7--76)                      30 (15--41)                         
  ≥ 12 LN examined                                                  1/1 (100)                     67/67 (100)                          98/100 (98.0)                   41/42 (97.6)                       4/4 (100)                          3/3 (100)                       0.664     206/209 (98.6)                  8/8 (100)                           0.737
  ypN0 *n* = 235, median (range)                                    13 (12--13)                   17 (2--36)                           18 (3--62)                      17 (7--37)                         21 (8--29)                         41 (16--43)                               17.5 (2--62)                    16 (8--43)                          
  ≥ 12 LN examined                                                  3/3 (100)                     70/90 (77.8)                         79/102 (77.5)                   26/30 (86.7)                       6/7 (86)                           3/3 (100)                       0.004     175/222 (78.8)                  12/13 (92)                          0.238
  R0---resection-rate                                               5/7 (71)                      209/212 (98.6)                       257/266 (96.6)                  102/102 (100)                      16/16 (100)                        9/9 (100)                       0.031     568/580 (97.9)                  30/32 (94)                          0.163
  Aboral resection margin \> 1 mm                                   7/7 (100)                     210/212 (99.1)                       263/266 (98.9)                  100/102 (98.0)                     15/16 (94)                         9/9 (100)                       0.474     573/580 (98.8)                  31/32 (97)                          0.351
  Circumferential resection margin \> 1 mm                          5/7 (71)                      197/212 (92.9)                       244/266 (91.7)                  98/102 (96.1)                      15/16 (94)                         9/9 (100)                       0.186     539/580 (92.9)                  29/32 (91)                          0.096
  Intraoperative local tumour cell dissemination                    2/7 (29)                      10/212 (4.7)                         14/266 (5.3)                    2/102 (2.0)                        1/ 16 (6)                          0/9 (0)                         0.112     26/580 (4.5)                    3/32 (9)                            0.279
  Quality of TME/PME ^b^                                                                                                                                                                                                                                                                                                                                   
  Mesorectal/intramesorectal plane                                  6/6 (100)                     190/196 (96.9)                       246/253 (97.2)                  91/92 (98.9)                       14/15 (93,3)                       8/9 (88,9)                                527/541 (97.4)                  28/30 (93)                          
  Muscularis propria plane                                          0/6 (0)                       6/196 (3.1)                          7/253 (2.8)                     1/92 (1.1)                         1/15 (6,7))                        1/9 (11,1)                      0.309     14/541 (2.6)                    2/30 (7)                            0.203
  Abdominoperineal excision                                                                                                                                                                                                                                                                                                                                
  All locations                                                     4/7 (57)                      36/212 (17.0)                        39/266 (14.7)                   14/102 (13.7)                      4/16 (25)                          2/9 (23)                        0.074     89/580 (15.3)                   10/32 (31)                          0.025
  \<6 cm lower third                                                4/4 (100)                     30/83 (36.1)                         30/82 (36.6)                    14/34 (41.2)                       4/5 (80)                           2/3 (67)                        \<0.001   74/199 (37.2)                   10/12 (83)                          \<0.001
  6--12 cm middle third                                             0/3 (0)                       6/84 (7.1)                           9/132 (6.8)                     0/43 (0)                           0/9 (0)                            0/5 (0)                         \<0.001   15/259 (5.8)                    0/17 (0)                            \<0.001
  Anastomosis                                                       2/7 (29)                      173/212 (81.6)                       224/266 (84.2)                  87/102 (85.3)                      12 /16 (75)                        7/9 (78)                        0.019     484/580 (83.4)                  21/32 (66)                          0.016
  Anastomotic leak                                                  0/2 (0)                       5/173 (2.9)                          10/224 (4.5)                    7/87 (8)                           0/12 (0)                           0/7 (0)                         0.466     22/484 (4.5)                    0/21 (0)                            1.0
  Morbidity                                                                                                                                                                                                                                                                                                                                                
  Total                                                             2/7 (29)                      39/212 (18.4)                        55/266 (20.7)                   29/102 (28.4)                      9/16 (56)                          3/9 (33)                        0.008     123/580 (21.2)                  14/32 (44)                          0.005
  Non-surgical                                                      0/7 (0,)                      9/212 (4.2)                          12/266 (4.5)                    7/102 (6.8)                        1/16 (6)                           0/9 (0)                         0.460     26/580 (4.5)                    1/32 (3)                            1.0
  Surgical                                                          2/7 (29)                      30/212 (14.1)                        43/266 (16.2)                   22/102 (21.6)                      8/16 (50)                          3/9 (33)                        0.006     95/580 (16.4)                   13/32 (41)                          0.001
  Postoperative 30-day mortality                                    1/7 (14)                      3/212 (1.4)                          1/266 (0.4)                     1/102 (1.0)                        0/16 (0)                           0/9 (0)                         0.116     5/580 (0.9)                     1/32 (3)                            0.282

^a^ R0 = 598 patients + R1 = 9 patients + R2 = 5 patients = 612 patients; ^b^ 41 patients missing due to unknown data.

cancers-11-00609-t004_Table 4

###### 

5-year rate of locoregional recurrence for 598 patients.

  Univariate Analysis                 Multivariate Analysis                                                 
  ----------------------------------- ----------------------- ------- ----------- ------- ----- ----------- -------
  Total                               598                     5.9%    3.9--7.9                              
  BMI WHO                                                                                                   
  BMI \< 18.5 kg/m^2^ underweight     5                       0%                          0.0               
  BMI 18.5--25 kg/m^2^ normal range   209                     3.7%    1.0--6.4            1.0               
  BMI 25--30 kg/m^2^ overweight       257                     8.7%    5.2--12.2           1.7   0.8--3.7    0.150
  BMI 30--35 kg/m^2^ obese class I    102                     1.1%    0.0--3.3            0.6   0.2--1.9    0.357
  BMI 35--40 kg/m^2^ obese class II   16                      23.6%   0.0--47.3           4.1   1.1--15.4   0.036
  BMI ≥ 40 kg/m^2^ obese class III    9                       11.1%   0.0--31.7   0.112   2.0   0.2--16.3   0.533
  BMI Groups                                                                                                
   Group 1: BMI 18.5--35              568                     5.5%    3.5--7.5            1.0               
   Group 2: BMI \<18.5 & ≥35          30                      15.4%   1.5--29.3   0.106   2.0   0.7--5.9    0.187
  Age                                                                                                       
   ≤65                                315                     5.6%    3.1--8.1                              
   \>65                               283                     6.4%    3.5--9.3    0.884                     
  Sex                                                                                                       
   Male                               394                     6.7%    4.2--9.2                              
   Female                             204                     4.3%    1.4--7.2    0.111                     
  Localisation                                                                                              
   \<6 cm                             202                     5.3%    2.2--8.4                              
   6--12 cm                           271                     7.1%    4.0--10.2                             
   12--16 cm                          125                     4.3%    0.6--8.0    0.641                     
  UICC-stage                                                                                                
   I                                  150                     4.3%    1.0--7.6            1.0               
   II                                 65                      11.4%   3.4--19.4           3.8   1.4--10.0   0.007
   III                                65                      9.2%    1.4--17.0           1.9   0.6--6.1    0.258
   y0                                 55                      0%                          0                 0.973
   yI                                 101                     3.0%    0--6.3              0.6   0.2--2.4    0.487
   yII                                74                      7.5%    1.0--14.0           1.7   0.6--5.2    0.321
   yIII                               88                      8.9%    2.6--15.2   0.003   2.5   0.9--6.8    0.067
  Abdominoperineal excision                                                                                 
   No                                 509                     5.4%    3.4--7.4                              
   Yes                                89                      8.9%    2.6--15.2   0.104                     
  ASA-Score ^a^                                                                                             
   ASA 1&2                            481                     5.0%    3.0--7.0            1.0               
   ASA 3&4                            113                     10.6%   4.3--16.9   0.040   2.1   1.0--4.5    0.042
  CEA-level ^b^                                                                                             
   Normal (\<5 ng/L)                  432                     5.9%    3.5--8.3            1.0               
   Elevated (≥5 ng/L)                 88                      4.9%    0.2--9.6    0.389   1.9   0.9--3.9    0.075

^a^ 4 Patients excluded due to unknown ASA-Score, ^b^ 78 Patients excluded due to unknown CEA-level.

cancers-11-00609-t005_Table 5

###### 

5-year rate of distant metastases of 598 patients.

  Univariate Analysis                 Multivariate Analysis                                                   
  ----------------------------------- ----------------------- ------- ------------ --------- ----- ---------- ---------
  Total                               598                     16.7%   13.6--19.8                              
  BMI WHO                                                                                                     
  BMI \< 18.5 kg/m^2^ underweight     5                       40.0%   0--82.9                1.7   0.4--7.2   0.493
  BMI 18.5--25 kg/m^2^ normal range   209                     16.2%   11.1--21.3             1.0              
  BMI 25--30 kg/m^2^ overweight       257                     17.3%   12.6--22.0             1.2   0.8--2.0   0.340
  BMI 30--35 kg/m^2^ obese class I    102                     11.9%   5.6--18.2              0.9   0.5--1.7   0.813
  BMI 35--40 kg/m^2^ obese class II   16                      34.0%   9.7--58.3              1.9   0.8--4.8   0.153
  BMI ≥ 40 kg/m^2^ obese class III    9                       22.2%   0--49.4      0.225     1.4   0.3--5.8   0.678
  BMI Groups                                                                                                  
   Group 1: BMI 18.5--35              568                     15.9%   12.8--19.0             1.0              
   Group 2: BMI \<18.5 or ≥35         30                      31.4%   14.3--48.5   0.034     1.6   0.8--3.1   0.177
  Age                                                                                                         
   ≤65                                315                     14.1%   10.2--18.0                              
   \>65                               283                     19.7%   14.8--24.6   0.085                      
  Sex                                                                                                         
   Male                               394                     16.3%   12.6--20.0                              
   Female                             204                     17.4%   12.1--22.7   0.861                      
  Localisation                                                                                                
   \<6 cm                             202                     13.8%   9.0--18.8                               
   6--12 cm                           271                     17.9%   13.2--22.6                              
   12--16 cm                          125                     18.8%   11.7--25.9   0.541                      
  UICC-stage                                                                                                  
   I                                  150                     9.8%    4.9--14.7              1.0              
   II                                 65                      23.1%   12.5--33.7             2.1   1.0--4.4   0.041
   III                                65                      30.7%   18.4--43.0             2.7   1.4--5.5   0.003
   y0                                 55                      1.9%    0--5.4                 0.2   0--1.3     0.086
   yI                                 101                     6.9%    2.0--11.8              0.6   0.2--1.4   0.250
   yII                                74                      23.3%   13.7--32.9             2.3   1.1--4.6   0.019
   yIII                               88                      30.3%   20.5--40.1   \<0.001   3.1   1.7--5.8   \<0.001
  Abdominoperineal excision                                                                                   
   No                                 509                     16.4%   13.1--19.7                              
   Yes                                89                      18.0%   9.8--26.2    0.313                      
  ASA-Score ^a^                                                                                               
   ASA 1&2                            481                     15.2%   11.9--18.5                              
   ASA 3&4                            113                     24.2%   15.8--32.6   0.052                      
  CEA-level ^b^                                                                                               
   Normal (\<5 ng/L)                  432                     14.1%   10.8--17.4             1.0              
   Elevated(≥5 ng/L)                  88                      31.6%   21.6--41.6   \<0.001   1.9   1.2--3.0   0.005

^a^ 4 Patients excluded due to unknown ASA-Score, ^b^ 78 Patients excluded due to unknown CEA-level.

cancers-11-00609-t006_Table 6

###### 

5-year overall survival for 598 patients.

  Univariate Analysis                  Multivariate Analysis                                                     
  ------------------------------------ ----------------------- ------- ------------- --------- ----- ----------- ---------
  Total                                598                     82.3%   79.2--85.4                                
  BMI WHO                                                                                                        
   BMI \< 18.5 kg/m^2^ underweight     5                       60.0%   17.1--100               1.7   0.4--7.2    0.458
   BMI 18.5--25 kg/m^2^ normal range   209                     82.3%   77.2--87.4              1.0               
   BMI 25--30 kg/m^2^ overweight       257                     81.3%   76.6--86.0              1.2   0.8--1.7    0.369
   BMI 30--35 kg/m^2^ obese class I    102                     88.2%   81.9--94.5              0.7   0.5--1.2    0.219
   BMI 35--40 kg/m^2^ obese class II   16                      68.8%   46.1--91.5              1.4   0.7--2.9    0.377
   BMI ≥ 40 kg/m^2^ obese class III    9                       77.8%   50.6--100     0.211     0.7   0.2--2.0    0.524
  BMI Groups                                                                                                     
   Group 1: BMI 18.5--35               568                     82.9%   79.8--86.0              1.0               
   Group 2: BMI \<18.5 or ≥35          30                      70.0%   53.5--86.5    0.023     1.1   0.7--1.9    0.652
  Age                                                                                                            
   ≤65                                 315                     90.8%   87.7--93.9                                
   \>65                                283                     72.8%   67.7--77.9    \<0.001                     \<0.001
  Sex                                                                                                            
   Male                                394                     83.5%   79.8--87.2                                
   Female                              204                     79.9%   74.4--85.4    0.471                       
  Morbidity                                                                                                      
   Yes                                 132                     76.5%   69.2--83.8                                
   No                                  466                     83.9%   80.6--87.2    0.004                       
  Localisation                                                                                                   
   \<6 cm                              202                     85.1%   80.2--90.0                                
   6--\<12 cm                          271                     80.4%   75.7--85.1                                
   12--16 cm                           125                     81.6%   74.7--88.5    0.176                       
  UICC-stage                                                                                                     
   I                                   150                     84.7%   79.0-- 90.4             1.0               
   II                                  65                      73.8%   63.0--84.6              1.2   0.7--2.0    0.476
   III                                 65                      63.1%   51.3--74.9              2.3   1.5--3.6    \<0.001
   y0                                  55                      98.2%   94.7--100               0.4   0.2--0.9    0.024
   yI                                  101                     97.0%   93.7--100               0.5   0.3--0.8    0.010
   yII                                 74                      74.3%   64.3--84.3              1.0   0.6--1.7    0.973
   yIII                                88                      78.4%   69.8--87.0    \<0.001   1.1   0.7-- 1.8   0.658
  Abdominoperineal excision                                                                                      
   No                                  509                     83.9%   80.8--87.0              1.0               
   Yes                                 89                      73.0%   63.8--82.2    0.001     1.9   1.3--2.9    0.001
  ASA-Score ^a^                                                                                                  
   ASA 1&2                             481                     86.3%   83.2--89.4              1.0               
   ASA 3&4                             113                     64.6%   55.8--73.4    \<0.001   3.2   2.3--4.4    \<0.001
  Pretherapy CEA level ^b^                                                                                       
   Normal (\<5 ng/mL)                  432                     84.3%   80.8--87.8              1.0               
   Elevated (≥5 ng/mL)                 88                      68.2%   58.4--78.0    \<0.001   1.9   1.3--2.6    \<0.001

^a^ 4 Patients excluded due to unknown ASA-Score; ^b^ 78 Patients excluded due to unknown CEA-level.
